{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:01:35Z","timestamp":1790146895316,"version":"4.0.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Leptomeningeal metastasis (LM) is associated with poor outcomes in non-small cell lung cancer (NSCLC), and clinical evidence for\n                      <jats:italic>KRAS G12C<\/jats:italic>\n                      inhibition in this setting is limited. We examined clinical outcomes and cerebrospinal fluid (CSF) molecular changes in patients with\n                      <jats:italic>KRAS G12C<\/jats:italic>\n                      -positive LM who received glecirasib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective case series included patients treated with glecirasib at Affiliated Brain Hospital of Nanjing Medical University between January 2025 and June 2026. Intracranial progression-free survival (iPFS) and overall survival (OS) were summarized descriptively. Exploratory serial CSF circulating tumor DNA (ctDNA) analyses were performed in two selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven patients were included, with a median observed follow-up of 6.3 months (range, 2.4-9.6). The best overall LM assessment was response in five patients, stable disease in one, and progressive disease in one. Two patients developed LM progression and one patient died; median iPFS and OS were not reached. In the patient with acquired\n                      <jats:italic>KRAS G12C<\/jats:italic>\n                      , CSF ctDNA detected the alteration at LM progression after EGFR-TKI therapy.\n                      <jats:italic>KRAS G12C<\/jats:italic>\n                      variant allele frequency decreased after glecirasib initiation and subsequently increased at progression, accompanied by the emergence of\n                      <jats:italic>KRAS G12D<\/jats:italic>\n                      and increased\n                      <jats:italic>CDK4\/MDM2<\/jats:italic>\n                      amplification. In the patient with primary\n                      <jats:italic>KRAS G12C<\/jats:italic>\n                      ,\n                      <jats:italic>KRAS G12C<\/jats:italic>\n                      and\n                      <jats:italic>TP53<\/jats:italic>\n                      variant allele frequencies initially decreased but later rose at the last CSF assessment, without concurrent radiographic, cytological, or symptomatic evidence of LM progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective series of seven patients, glecirasib monotherapy was associated with LM disease control in six patients, suggesting possible activity in KRAS G12C-positive NSCLC with LM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1956344","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:18:30Z","timestamp":1790144310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glecirasib treatment in KRAS G12C-positive non-small cell lung cancer with leptomeningeal metastasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunfei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, The People\u2019s Hospital of Linquan County","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The People\u2019s Hospital of Linquan County","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Jiamusi University","place":["Jiamusi, Heilongjiang, China"]},{"name":"Brain Metastases Diagnosis and Treatment Centre, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[{"name":"Brain Metastases Diagnosis and Treatment Centre, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencun","family":"Fang","sequence":"additional","affiliation":[{"name":"Brain Metastases Diagnosis and Treatment Centre, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[{"name":"Brain Metastases Diagnosis and Treatment Centre, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now183","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.140","article-title":"The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study","volume":"37","author":"Zheng","year":"2026","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.09.013","article-title":"Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment","volume":"174","author":"Wang","year":"2022","journal-title":"Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108593","article-title":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","volume":"205","author":"Xie","year":"2025","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0001","article-title":"Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism with cetuximab or SHP2 inhibitor JAB-3312","volume":"5","author":"Wang","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00700-y","article-title":"The path to leptomeningeal metastasis","volume":"24","author":"Remsik","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00975-5","article-title":"Leveraging molecular and immune-based therapies in leptomeningeal metastases","volume":"37","author":"Wilcox","year":"2023","journal-title":"CNS Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.01.006","article-title":"A single-arm phase 2 study of sotorasib plus carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC with KRAS G12C mutation (WJOG14821L, SCARLET)","volume":"20","author":"Akamatsu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107960","article-title":"Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)","volume":"197","author":"Johnson","year":"2024","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S383662","article-title":"A long overdue targeted treatment for KRAS mutations in NSCLC: spotlight on adagrasib","volume":"13","author":"Brazel","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04519-9","article-title":"Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis","volume":"165","author":"Wijaya","year":"2023","journal-title":"J Neurooncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1409383","article-title":"Applications of cerebrospinal fluid circulating tumor cells and circulating tumor-derived DNA in diagnosis, prognosis, and personalized treatment of CNS metastases","volume":"14","author":"Pentsova","year":"2024","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04471-8","article-title":"Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases","volume":"165","author":"Bai","year":"2023","journal-title":"J Neurooncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01218-8","article-title":"Serial monitoring of cerebrospinal fluid in patients with leptomeningeal metastases in lung cancer via the Ommaya reservoir as a predictive indicator of therapeutic efficacy and clinical prognosis","volume":"10","author":"Fang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-026-05520-8","article-title":"Cerebrospinal fluid ctDNA as a prognostic and disease-activity biomarker in leptomeningeal metastases: systematic review, meta-analysis, and implications for CSF-guided care","volume":"177","author":"Sankar","year":"2026","journal-title":"J Neurooncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-026-03407-z","article-title":"Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes","volume":"134","author":"Wang","year":"2026","journal-title":"Br J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14583-1","article-title":"Cerebrospinal fluid circulating tumor DNA (ctDNA) as a biomarker for CNS metastases in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods","volume":"25","author":"Olayode","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1956344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:18:31Z","timestamp":1790144311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1956344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1956344"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1956344","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1956344"}}